share_log

Tharimmune | ARS: Annual Report to Security Holders

SEC announcement ·  Mar 22 23:12
Summary by Futu AI
Tharimmune, Inc., a clinical-stage biotechnology company, announced the signing of a patent license agreement with Avior Inc. on November 3, 2023, granting exclusive rights to develop, manufacture, and commercialize therapeutic candidates TH104 and TH103 globally. The FDA approved an IND application for TH104 in February 2023, targeting chronic pruritis in primary biliary cholangitis (PBC) patients. Tharimmune is also advancing an early-stage pipeline focusing on immuno-oncology targets such as HER2, HER3, and PD-1. The company's financial statements for the year ended December 31, 2023, indicate a net loss of $9.3 million, with research and development expenses increasing due to pre-clinical activities and licensing fees. Tharimmune raised approximately $13.6 million through public offerings to support operations. The company's future plans include clinical trials for TH3215 and TH1940, with the need for additional funding to continue operations, raising substantial doubt about its ability to continue as a going concern.
Tharimmune, Inc., a clinical-stage biotechnology company, announced the signing of a patent license agreement with Avior Inc. on November 3, 2023, granting exclusive rights to develop, manufacture, and commercialize therapeutic candidates TH104 and TH103 globally. The FDA approved an IND application for TH104 in February 2023, targeting chronic pruritis in primary biliary cholangitis (PBC) patients. Tharimmune is also advancing an early-stage pipeline focusing on immuno-oncology targets such as HER2, HER3, and PD-1. The company's financial statements for the year ended December 31, 2023, indicate a net loss of $9.3 million, with research and development expenses increasing due to pre-clinical activities and licensing fees. Tharimmune raised approximately $13.6 million through public offerings to support operations. The company's future plans include clinical trials for TH3215 and TH1940, with the need for additional funding to continue operations, raising substantial doubt about its ability to continue as a going concern.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.